Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05523765 · ClinicalTrials.gov registry record · Phase 2
A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis
A Phase 2 study, sponsored by Priovant Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT05523765 is a Phase 2 study that has completed, run by Priovant Therapeutics. The registered enrollment target is 26 participants.
The verdict
NCT05523765, a Phase 2 study, has completed, sponsored by Priovant Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
Interventions
- DRUG Brepocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2024-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05523765
The ClinicalTrials.gov registry entry for NCT05523765 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Priovant Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brepocitinib is the first listed.
NCT05523765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05523765 about?
NCT05523765 is a clinical study titled "A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis". This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with active intermediate, posterior, or pan non-infectious uveitis (NIU).
What is the current status of trial NCT05523765?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2022-11-14. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT05523765?
The interventions under investigation include: Brepocitinib (DRUG).
Who is sponsoring clinical trial NCT05523765?
This trial is sponsored by Priovant Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.